ABN AMRO Capital Life Sciences (AAC LS) has announced that it has led a EUR 22m series-A financing of Amsterdam Molecular Therapeutics BV (AMT). The syndicate was completed by Advent Venture Partners, Gilde Investment Management and Crédit Agricole Private Equity. Sander Slootweg from ABN AMRO Capital Life Sciences has joined the company’s supervisory board.
BCEP II follows a long-hold private equity strategy, with an investment period of 15 years
Combined companies will pursue a buy-and-build strategy, acquiring fitness studio chains
Marc Seeger joins the firm's Düsseldorf-based corporate and M&A team from Hengeler Mueller
GP acquires the automotive networked systems business as part of a succession solution